NSE filing, NSE: ICICILIFE. Summary written from the filing by ALFA Finder's alert engine.
ICICI Life Insurance Ltd: key numbers
- Share price
- ₹438.90
- Market cap
- ₹63,693 Cr
- Revenue (annual)
- ₹63,467 Cr
- Net profit (annual)
- ₹1,600 Cr
- P/E (TTM)
- 36.2×Sector 20.6×
- Promoter holding
- 74.70%+1.97% QoQ
- FII holding
- 9.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from ICICI Life Insurance Ltd
All →ICICI Life Insurance Employee Stock Options
ICICI Life allotted 2,520 equity shares under its Employees Stock Unit Scheme (2023) on November 4, 2026. The shares rank pari passu with existing equity.
ICICI Life Insurance Employee Stock Options
ICICI Prudential Life Insurance allotted 2,697 equity shares under its ESUS 2023 scheme on October 21, 2026. No transaction value is disclosed for this ESOP allotment.
ICICI Life Insurance Legal & Regulatory
ICICI Life Insurance received an Income Tax rectification order for Assessment Year 2023, resulting in a total financial impact of ₹591.42 Crore.
- Value
- ₹591.4 Cr
- From
- Assistant Commissioner of Income Tax, Mumbai
ICICI Life Insurance Legal & Regulatory
ICICI Life Insurance received an income tax rectification order for Assessment Year 2023, resulting in a total incremental tax and interest demand of ₹230.19 Crore.
- Value
- ₹230.2 Cr
- From
- Income Tax Department
ICICI Life Insurance Legal & Regulatory
ICICI Life Insurance received an income tax rectification order for AY 2024, resulting in a reduced tax demand and adjusted interest impact of ₹278.90 Crore.
- Value
- ₹278.9 Cr
- From
- Assistant Commissioner of Income Tax
ICICI Life Insurance Legal & Regulatory
ICICI Life Insurance received an Income Tax rectification order for AY 2024, resulting in incremental interest of ₹ 40.96 Lakhs. The company has appealed the order.
- Value
- ₹0.41 Cr
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.